Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Exactly!! Such an appropriate stock symbol for this "company".
Absolutely correct! Something has been seriously wrong here, actually very, very seriously wrong for a long, long time!
Would you please explain/elaborate what you are indicating as an IMUN 400,000 share range of dilution for as long as you remember. Thank you.
What?? In the entire history of IMUN and going back to when it was previously named TNI Biotech, Inc (TNIB) there has NEVER been dilution?? Really!
I am just asking, just asking are you SURE that a 1:1000 reverse split would take a $0.30 to $0.14 price per share to equal, after adjustment for the 1:1000 reverse split, to $30.00 to $ 14.00 share prices???
Once again, are you SURE your math is correct???
Are you SURE your math is correct??
Where did you see in official writing that Dr. Fauci has given LDN the OK for anything?? Would appreciate the link/citation. Thank you.
I assume you are absolutely correct, but need accountancy input.The whole situation with Cytocom, Inc. going back to its inception from IMUN in 2014 and all of the financial manipulations since needed/needs to be put under a forensic analysis. There may be at least IMUN shareholders actions that should have been taken long ago!
That is not how I understand this proposed merger.The proposal is for a merger of an existing subsidiary company of CBLI with Cytocom wherein Cytocom will own the 61% interest and CBLI will own 39% of the subsidiary new company post merger. Cytocom will not own 61% of CBLI.
Please correct my understanding if not correct.
Could you explain or direct me to the information that Cytocom, Inc, "spent over 1/2 million on an INDA." Thank you.
As with the website these recently released statements are patently misleading.There have been NO Phase 2 studies performed under the direct control (IND) of the FDA for either IMUN or Cytocom specifically regarding any of the indications so indicated. Thus, Phase 3-ready is not yet appropriately established under FDA regulatory parameters for either IMUN or Cytocom.
Cytocom, Inc. NEVER announced a New Drug Application (NDA) but clearly indicated in 6/9/20 press release that they purportedly filed with the FDA an Investigational New Drug Application (INDA) in order to proceed to do proposed clinical studies. They are not remotely ready to file an NDA yet.
That statement is NOT an Approval by the FDA to commence a Phase 3 clinical trial!!
Great response! The only comment is that I am not aware that the FDA gave a green light to a Phase 3 (or even a late Phase 2) for LDN and Crohn's Disease at any time as yet.
Once again, a most excellent and accurate response/assessment of the the issues facing IMUN!!
Four very, very pertinent and consequential questions for IMUN that you put forth!
Must compliment your excellent post! Very well framed and on target. Actually, the potential for a positive primary endpoint result in the Beaumont sponsored trial would be THE most important event for IMUN since its inception. Although, not surprisingly, IMUN has no connection to the clinical study they best be ready exactly as you described in your first sentence of your post!
There does not need to be more than one sponsor. But, if IMUN was involved do you not think that they would want to be also listed. Why Not?? This study is an Investigator's study. Now should the results prove favorable, I believe IMUN will have probable passive benefit.
What are you indicating?? A study from 2010-never completed. No results reported! And IMUN wasn't even in existence at that time.
Absolutely incredible! First-the word is patent and not patient protection.
Second-have no idea what patent application you are quoting from but the one you are covers Protozoal infections not Viral Infections. Need to find another quote from said patent.
I do not believe the William Beaumont Hospital naltrexone/ketamine is related to IMUN. Note-only one sponsor indicated-William Beaumont Hospital and absolutely no mention of Lodonal under Other Names for naltrexone. Only ReVia (the 50 mg oral form) and Vivitrol(the intramuscular injection form).
What specific clinical trials posted on clinicaltrials.gov are you referring to that Handley should be announcing? The William Beaumont Hospital COVID-19 naltrexone/ketamine study? Any others?
What in blazes do you mean LDN "has proven to be effective against autoimmune diseases"?? How do you define proven-what well designed and appropriately conducted clinical studies under the FDA or any other competent regulatory agency have been conducted to indicated such a claim?? Cite them for us!
I was not addressing my question to you at all. You most inappropriately responded for some other poster.
I have asked twice previously--what is ITX401. Perhaps you have some information??
Once more asking-what is ITX401??
Also do not know if that is true that naltrexone used to inhibit viral(assume coronavirus?)growth in Japan, but what IS TRUE it was one of 4 out of 15 initial drugs assessed for antiviral activity against H1N1 viral strains that did show viral inhibition in in vitro cellular studies. This was performed and published by research group in Singapore. Published in June, 2019 Frontiers in Immunology journal. But many more studies needed to prove true therapeutic efficacy in humans.
How do you know that "Most companies are focusing on vaccines not on treatment"? Reliable source(s) for that information please.
Why do you post for public consideration such statements as LDN has "...PROVEN TO BE VERY EFFECTIVE TREATING MALARIA AND HIV..." Proven How? and When?
Here is another question for you-What is ITX401??
What in absolute blazes are you indicating?? A study of combination of Lodonal and IRT-101 (methionine enkephalin) antibodies and coronavirus??
Would be most helpful if you could cite the IMUN filing(s) that the Stock Ownership of Management data that you posted were listed. Thank you.
Noreen Griffin being a puppet of the IMUN Board?? That one Is highly unlikely! Under the influence of the RJ Daily band of shareholders (only one of which was on the Board)-Yes! Either way she was and is and will always be an unmitigated incompetent disaster.
Completely correct!. The pathetic and significantly inept NG is definitely actively involved with IMUN.
Yes, correct. Professor Fengping Shan was considered the CSO (Chief Scientific Officer) of IMUN, but I am not certain that he continues to hold that position currently or even has any continuing affiliation with IMUN. Not sure-perhaps you or others may know?
Thank you. Yes, there was an agreement with Hubei Qianjiang Pharmaceutical Co., Ltd. located in Qianjiang City in Hubei Province to co-develop MENK for cancer therapeutics when IMUN was named TNI Biotech, Inc. back in Octover of 2012 with a Supplemental agreement made with the same Company later in 2014. Unless someone has more accurate and updated information to offer, absolutely NOTHING came of that endeavor as with all others under the profoundly inept management of the disasterously incompetent Griffin.
Where in Hubei Province of China is IMUN located as you so assuredly indicated? Most interested to know. Thank you.
Yes, you are exactly correct!! The grossly incompetent NG is indeed still actively in the background of the IMUN situation!!
Reminds one of the centuries old figure of speech--"Jack of all trades, master of none!"